Pendulum Therapeutics

Pendulum Therapeutics believes therapies developed using evidence-based microbiome science and DNA sequencing can help heal the body from within. Armed with 13 patents and 42 pending, the company introduced its flagship product Pendulum Glucose Control, a medical probiotic, in 2020 and demonstrated its efficacy in lowering blood sugar spikes and reducing A1C in a published clinical trial. Founded in 2013 by a diverse team of scientists with deep microbiology, biochemistry, computational, and clinical expertise, Pendulum has raised $111 million to date from Meritech Capital, Sequoia Capital, True Ventures, Khosla Ventures, AME Cloud Ventures and Mayo Clinic among others. Pendulum Therapeutics is headquartered in San Francisco.

Pendulum Therapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical, Therapeutics, Health Diagnostics sector. The company focuses on Biotechnology and has secured $21.8B in funding across 180 round(s). With a team of 11-50 employees, Pendulum Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series C - Pendulum Therapeutics, raised $Unknown amount. Discover more about their projects, partnerships, and impact on our platform.